Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study-Reference-Cited by-同舟云学术

Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study

Published:2018-05 Issue: Volume:119 Page:14-20
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Fujimoto Daichi^ORCID,Yoshioka Hiroshige,Kataoka Yuki,Morimoto Takeshi,Kim Young Hak,Tomii Keisuke,Ishida Tadashi,Hirabayashi Masataka,Hara Satoshi,Ishitoko Manabu,Fukuda Yasushi,Hwang Moon Hee,Sakai Naoki,Fukui Motonari,Nakaji Hitoshi,Morita Mitsunori,Mio Tadashi,Yasuda Takehiro,Sugita Takakazu,Hirai Toyohiro

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. Cancer statistics, 2017

2. Non-small cell lung cancer: epidemiology risk factors, treatment, and survivorship;Molina;Mayo Clin. Proc.,2008

3. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

4. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Immune-Related Adverse Events and the Efficacy of Anti–PD-(L)1 Monotherapy in Non–Small Cell Lung Cancer: Adjusting for Immortal-Time Bias;Cancer Research and Treatment;2024-07-15

2. Comparison of treatment outcome between first‐line combination immunotherapy (anti‐PD‐L1 or anti‐PD1) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital;Cancer Medicine;2024-07

3. Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung disease;Journal of Thoracic Disease;2024-05

4. Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study;European Journal of Cancer Care;2024-03-19

5. First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17;European Journal of Cancer;2024-03